Los Angeles Capital Management LLC Has $238,000 Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Los Angeles Capital Management LLC lowered its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 38.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,911 shares of the company’s stock after selling 3,737 shares during the period. Los Angeles Capital Management LLC’s holdings in Kymera Therapeutics were worth $238,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Quest Partners LLC acquired a new stake in shares of Kymera Therapeutics during the 4th quarter valued at $78,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Kymera Therapeutics by 352.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,423 shares of the company’s stock worth $164,000 after purchasing an additional 5,002 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in shares of Kymera Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 7,359 shares of the company’s stock valued at $187,000 after buying an additional 1,866 shares during the period. Aigen Investment Management LP bought a new position in Kymera Therapeutics in the 4th quarter valued at approximately $233,000. Finally, Clear Harbor Asset Management LLC acquired a new stake in Kymera Therapeutics during the 4th quarter worth approximately $255,000.

Analyst Ratings Changes

Several equities analysts have recently issued reports on KYMR shares. Truist Financial raised their price target on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the company a “buy” rating in a research note on Friday, March 1st. HC Wainwright reaffirmed a “buy” rating and set a $46.00 target price on shares of Kymera Therapeutics in a research report on Monday, June 17th. Finally, Oppenheimer cut their target price on Kymera Therapeutics from $53.00 to $52.00 and set an “outperform” rating on the stock in a report on Friday, May 3rd. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.70.

Kymera Therapeutics Price Performance

NASDAQ KYMR opened at $30.22 on Friday. Kymera Therapeutics, Inc. has a one year low of $9.60 and a one year high of $45.31. The business has a 50 day simple moving average of $34.21 and a 200 day simple moving average of $34.09. The stock has a market capitalization of $1.85 billion, a P/E ratio of -12.04 and a beta of 2.25.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.04. The company had revenue of $10.30 million during the quarter, compared to analyst estimates of $14.24 million. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 31.92%. Kymera Therapeutics’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.70) EPS. Equities analysts expect that Kymera Therapeutics, Inc. will post -2.86 earnings per share for the current year.

Insider Activity

In related news, Director Bruce Booth sold 16,740 shares of the business’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $35.45, for a total value of $593,433.00. Following the completion of the sale, the director now directly owns 803,792 shares of the company’s stock, valued at approximately $28,494,426.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Bruce Booth sold 16,740 shares of Kymera Therapeutics stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $35.45, for a total value of $593,433.00. Following the completion of the sale, the director now owns 803,792 shares of the company’s stock, valued at approximately $28,494,426.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Joanna Horobin sold 8,500 shares of the firm’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $32.99, for a total transaction of $280,415.00. The disclosure for this sale can be found here. Company insiders own 15.82% of the company’s stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.